Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2008

AMRI Expands Foothold in India with Acquistion of FineKem

  • AMRI purchased FineKem Laboratories, a manufacturing facility located in Aurangabad, India. This acquisition is expected to accelerate AMRI’s ability to make custom pilot-scale intermediates in this country. The purchase also reportedly ensures the addition of ISMN to AMRI’s generics portfolio.

    This transaction expands on AMRI’s recent acquisition of manufacturing facilities in Aurangabad and Navi Mumbai, both in India, in July 2007. It also complements the company’s current chemical development process capabilities in Hyderabad, India.

    AMRI says that business is expected to commence in the second quarter. The company intends to implement upgrades over the next few months to bring the existing facilities into compliance with FDA regulations for manufacturing clinical trial materials and commercial drug substances.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »